Metabolic disturbances and renal stone promotion on treatment with topiramate: a systematic review: Metabolic disturbances on treatment with topiramate
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
AIMS: The use of topiramate, which is prescribed for the management of epilepsy, for migraine headache prophylaxis and as a weight-loss agent, has been associated with the development of metabolic acidosis, hypokalaemia and renal stone disease. We systematically reviewed all the literature. METHODS: The systematic review of the literature was realized using the principles underlying the UK Economic and Social Research Council guidance on the conduct of narrative synthesis and the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement. RESULTS: Fourty-seven reports published between 1996 and 2013 were retained for the final analysis. Five case-control studies and six longitudinal studies addressed the effect of topiramate on acid-base and potassium balance. A significant tendency towards mild-to-moderate hyperchloraemic metabolic acidosis (with bicarbonate ≤21.0 mmol l(-1) in approximately every third case) and mild hypokalaemia (with potassium ≤3.5 mmol l(-1) in 10% of the cases) was noted on treatment with topiramate, which was similar in children and adults. A single study observed that topiramate causes mild hyperuricaemia in male adults. A tendency towards hypocitraturia, a recognized promoter of renal stone formation, was noted in all patients on topiramate. CONCLUSIONS: Increasing evidence supports the use of topiramate. Topiramate is generally well tolerated, and serious adverse events are rare. Nonetheless, the present systematic review of the literature indicates that its use is linked with the development of acidosis, hypokalaemia, hyperuricaemia and hypocitraturia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Guide to receptors and channels (GRAC), 5th edition
Alexander, S., Mathie, A., & Peters, J. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01649_1.x · Cited by 1,947
Biochemical and stone-risk profiles with topiramate treatment
Welch, B. J., Graybeal, D., Moe, O. W., Maalouf, N. M., & Sakhaee, K. (2006) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2006.07.003 · Cited by 126
Topiramate-Induced Nephrolithiasis
Kuo, R. L., Moran, M. E., Kim, D. H., Abrahams, H. M., White, M. D., & Lingeman, J. E. (2002) · Journal of Endourology · doi:10.1089/089277902753752188 · Cited by 76
Cited by
Garvey, W. T., Mechanick, J. I., Brett, E. M., Garber, A. J., Hurley, D. L., Jastreboff, A. M., Nadolsky, K., Pessah-Pollack, R., & Plodkowski, R. (2016) · Endocrine Practice · doi:10.4158/ep161365.gl · Cited by 1,914
Pringsheim, T., Okun, M. S., Müller-Vahl, K., Martino, D., Jankovic, J., Cavanna, A. E., Woods, D. W., Robinson, M., Jarvie, E., Roessner, V., et al. (2019) · Neurology · doi:10.1212/wnl.0000000000007466 · Cited by 565
Drug-induced kidney stones and crystalline nephropathy: pathophysiology, prevention and treatment
Daudon, M., Frochot, V., Bazin, D., & Jungers, P. (2018) · Drugs · doi:10.1007/s40265-017-0853-7 · Cited by 191
Nourredine, M., Jurek, L., Angerville, B., Longuet, Y., de Ternay, J., Derveaux, A., & Rolland, B. (2021) · CNS Drugs · doi:10.1007/s40263-020-00780-y · Cited by 26
“3 mmol/L), and hyperuricemia (almost exclusively in male subjects); high doses of topiramate (≥ 300 mg/day) can cause nephrolithiasis associated with hypocitraturia [85].”
Background
Metadata
- Authors
- Dell'Orto, V. G., Belotti, E. A., Goeggel-Simonetti, B., Simonetti, G. D., Ramelli, G. P., Bianchetti, M. G., & Lava, S. A. G.
- Venue
- British Journal of Clinical Pharmacology
- Publisher
- Wiley
- Published
- 2014-05-22
- Volume
- 77
- Issue
- 6
- Pages
- 958-964
- ISSN
- 0306-5251 (ISSN-L)
- OpenAlex
- W1529190035
- Cited by
- 69
- References
- 3
- FWCI
- 1.02
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.